Emergent BioSolutions (EBS) Tops Q3 EPS by $1.27
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $4.69 +3.08%
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $1.37, $1.27 better than the analyst estimate of $0.10. Revenue for the quarter came in at $293.8 million versus the consensus estimate of $290.33 million.
GUIDANCE:
Emergent BioSolutions sees FY2024 revenue of $1.065-1.125 billion.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Robinhood Ventures Fund II opens at $22.50, IPO at $25
- Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
- SuperCom (SPCB) Tops Q3 EPS by 43c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
